CERO Therapeutics Holdings, Inc.
corporate_fare Company Profile
CERO Therapeutics Holdings, Inc. (OTC:CERO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for CERO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for CERO spans 10-Q, 424B3, 10-K, 8-K.
Recent high-impact activity:
- CERo 10-Q: Going Concern Doubt, $650K Cash, Pending Subsidiary Sale to SRX
- CERO Therapeutics Files Prospectus Supplement Incorporating Dire 10-K, Revealing Ongoing Dilutive Financings and Going Concern Warning
- CERO Therapeutics Faces Going Concern Warning Amidst Nasdaq Delisting and Highly Dilutive Financing
- Registers 729.6M Shares for Resale from Highly Dilutive Convertible Note
- CERO Secures $350K in Highly Dilutive Convertible Note Financing
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 20,236 shares in CERO as of the October 30, 2026 settlement, a 1911.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 93.6% of CERO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.